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Background: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes
overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their
identification is of real interest because specific inhibitors have been developed.
Methods and results: We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with
synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first
without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate
treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real
improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a
complete response on mediastinal lymph nodes and regeneration on bone metastases.
Conclusion: This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves
a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors.Introduction
Malignant tumours of the parotid gland are unusual.
They represent fewer than 5% of tumours in the head
and neck region (Spiro 1991). Salivary gland carcinomas
are a heterogenous group of tumours with great diversity
in histological appearance and biological behaviour. Some
tumors are less malignant and have a good prognosis
while others progressing to recurrence, metastases and
death of the individual. Cystadenocarcinoma is a rare
malignant tumour characterized by predominantly cys-
tic growth that often exhibits intraluminal papillary growth.
These tumours, which have no identified risk factors, occur
mainly in the major salivary glands and particularly in the
parotid. The tumorigenesis of these tumours is still poorly
understood. Despite ongoing advances in surgery, radiation
therapy and chemotherapy, the 5-year survival rate for sal-
ivary gland malignancies has not changed significantly dur-
ing the last few decades. But this will certainly change soon
thanks to major advances in fundamental research. Since
the discovery of the role of RAS oncogenes in tumorigen-
esis, there has been an explosion of research in the signal
transduction area. A key RAS effector pathway involves* Correspondence: boyrie.sabrina@claudiusregaud.fr
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in any medium, provided the original work is pthe kinase cascade RAF/MEK/ERK. The B-type RAF
proto-oncogene (BRAF) V600E mutation is a represen-
tative oncogenic mutation. This mutation has emerged
as a prognostic variable for several tumours such as thyroid
(Kim et al. 2012). Somatic mutations of BRAF have been
described in Head and Neck Squamous Cell Carcinoma
(HNSCC) (Weber et al. 2003). Novel agents are being de-
signed specifically to inhibit several biochemical pathways
in the pathogenesis of cancer. We report here the case of a
patient with an agressive cystadenocarcinoma of the par-
otid with a BRAF mutation treated with a BRAF inhibitor.Case report
Mr B. is a 69 year-old man with no significant past med-
ical history. He presented to our Institute with a left pre-
tragus mass that appeared a few weeks ago. His general
practitioner ordered a Computed Tomography (CT) scan
then a Magnetic Resonance Imaging (MRI) that revealed a
bifocal parotid mass. The first nodule extended into the
superficial lobe of the parotid and the second through the
angle of the mandible with a marked osteolysis. A nodule
was also seen at the upper front of the maxillary left sinus
without continuity with previous one. Clinically no mu-
cosal lesion was identified. The fine needle aspiration bi-
opsy of the parotid lesion exhibited glandular epithelialn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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strated a papillary adenocarcinoma suggesting a cystade-
nocarcinoma. Immunohistochemical assessment of HER2
showed grade 2+ overexpression but no HER2 gene ampli-
fication by FISH (fluorescence in-situ hybridization). Posi-
tron Emission Tomography (PET) staging showed distant
metastases. Multiple bone hyperfixations were localized in
C3 right costal arch, C6 with posterior wall destruction, L4
pedunculate, left femur and pelvis.
A chemotherapy was initiated on July 2011. Three cy-
cles of cisplatin 100 mg/m2 and 5-fluorouracil 1000 mg/
m2/d (J1-J4) were delivered with good tolerance. The
CT scan evaluation revealed a stabilization of the mass
developed at the expense of the superficial lobe of the
parotid but a marked progression of bone localizations
of the malar mass (33 mm versus 14 mm) and of mandibleFigure 1 Comparison of CT scans realized before and after two mont
2012. D, E, F: CT realized on June 2012 A, D: Reduction of tissue infiltration ar
(after injection of contrast agent): Complete regression of mediastinal lymph
Notice cortical bone regeneration of arcuate line of ilium.osteolysis with pathological fracture. Distant bone metas-
tases progressed too on the MRI with an epidural exten-
sion of C6 damage and appearance of T8 and L5 lesions.
In October 2011, palliative radiation therapy was admin-
istered on the primary parotid mass, the adjacent mandible
lesion and on symptomatic distant bone localizations (C6
and L4). The dose delivered was 30 Gy in 10 fractions.
The April 2012 CT scan evaluation reported a discrete
regression of the irradiated parotid mass but a further pro-
gression of the malar mass measured at 53 mm. Moreover,
enlarged mediastinal lymph nodes appeared in 2R, 4R and
7 as well as multiple osseous sites throughout the pelvis
and spine.
Given the aggressiveness and resistance of this disease
to radio-chemotherapy, an additional molecular analysis
was requested to attempt to identify mutations on EGFR,hs of treatment with a BRAF inhibitor. A, B, C: CT realized on April
ound malar bone destruction, especially on the sinusal component. B, E
nodes in station 4R. C, F (bone window): Left iliac bone regeneration.
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for BRAF. A polymerase chain reaction followed by an
allele specific oligonucleotide revealed a V600E mutation
of BRAF.
A compassionate treatment with a BRAF inhibitor
(Vemurafenib) was started at a dose of 240 mg bid for
2 months after approval of internal ethic committee. The
patient reported a great improvement in clinical condition
from the first month. His fatigue declined allowing him to
enjoy activities such as gardening. His vision improved
with ptosis regression. Clinical examination found a clear
regression of the malar mass. The CT scan obtained after
2 months of treatment confirmed the good clinical impres-
sion. The malar mass regressed by 42% (60 × 47 × 53 mm
versus 46 × 42 × 45 mm) (Figure 1A,B). Mediastinal lymph
nodes showed a complete response (Figure 1B,E). Bone re-
generation was seen on pelvis (Figure 1C,F) and spine.
Discussion
The RAF/MEK/ERK signal transduction cascade is an
important mediator of a number of cellular outcomes in-
cluding growth, proliferation and survival. The BRAF gene
is one of the human isoforms of RAF activated by onco-
genic RAS and leading to cooperative effects in cells
responding to growth factor signals.
Mutations of BRAF have been described in about 15%
of all human cancers (Davies et al. 2002). In contrast to
melanoma or colorectal cancer (Loupakis et al. 2009),
these mutations are relatively rare events in HNSCC. In
their series of 89 HNSCC, Weber et al. reported only 3%
with activating BRAF mutations (Weber et al. 2003). Lopez
et al. showed no BRAF mutation in both sinonasal squa-
mous cell carcinoma and intestinal-type sinonasal adeno-
carcinoma (Lopez et al. 2012). However BRAF mutation
occurs in approximately half of papillary thyroid cancers.
This mutation, correlated with high-risk clinicopathologi-
cal factors and poor clinical outcome, is a poor prognostic
marker in these papillary thyroid cancers (Kim et al. 2012).
BRAF mutation is also a poor predictor to response in
EGFR inhibitiors. Actually, potential mechanisms for the
lack of response to EGFR inhibition in HNSCC include
constitutive activation of signalling pathways independent
of EGFR, as well as genetic aberration causing dysregula-
tion of the cell cycle or mutation of downstream effectors
such as BRAF or KRAS.
Specific inhibitors of BRAF have been developped and
are now currently used in advanced melanoma with any
V600 BRAF mutation. Chapman et al. reported the results
of a phase 3 randomized clinical trial comparing vemu-
rafenib with dacarbazine in 675 patients with metastatic
melanoma with the BRAF V600E mutation. At 6 months,
overall survival was 84% in the vemurafenib group and
64% in the dacarbazine group. Response rates were 48%
for vemurafenib and 5% for dacarbazine (Chapman et al.2011). This study provided the proof that BRAF mtations
have strong oncogenic properties in this cancer. Vemura-
fenib is now approved for the treatment of metastatic mel-
anomas that harbor the BRAF V600E mutation.
For salivary glands carcinoma, immunohistochemical
procedures and molecular biological studies become more
and more important to classify this wide variety of tumours.
Overexpression of transmembrane receptors of type tyro-
sine kinase have been reported (HER2/neu (Cornolti et al.
2007), EGFR (Sorensen et al. 2006), C-kit in adenoid cystic
carcinoma (Sorensen et al. 2006)). Target therapies against
these receptors are now widely used in other cancers. Stud-
ies are ongoing in salivary gland carcinomas. BRAF muta-
tions could also be searched in these tumours, as our case
report points out. Although uncommon, it may identify a
subset of patients sensitive to targeted therapy. Our case
report suggests BRAF mutations are a strong oncogenic
driver in salivary gland carcinoma associated with aggres-
siveness, chemoresistance, metastatic properties and sensi-
tivity to BRAF inhibitors. A large collaborative academic
phase II trial should be performed in order to provide proof
of targeted treatment efficiency.
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